Cargando…

Levetiracetam-induced gingival hyperplasia

Levetiracetam is a new generation antiseizure medication which binds to synaptic vesicle protein SV2A and inhibits the release of neurotransmitters. Gingival hyperplasia is a common side effect of conventional antiseizure medications like phenytoin, but very rare with the newer ones. A 14-year-old b...

Descripción completa

Detalles Bibliográficos
Autores principales: James, J, Jose, J, Gafoor, VA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733520/
https://www.ncbi.nlm.nih.gov/pubmed/35848684
http://dx.doi.org/10.4103/jpgm.jpgm_1059_21
_version_ 1784846394205405184
author James, J
Jose, J
Gafoor, VA
author_facet James, J
Jose, J
Gafoor, VA
author_sort James, J
collection PubMed
description Levetiracetam is a new generation antiseizure medication which binds to synaptic vesicle protein SV2A and inhibits the release of neurotransmitters. Gingival hyperplasia is a common side effect of conventional antiseizure medications like phenytoin, but very rare with the newer ones. A 14-year-old boy was started on levetiracetam 250 mg twice daily after a generalized seizure. Five days later he presented with gingival swelling and painful oral aphthae, without lymphadenopathy or systemic symptoms. Blood investigations were normal. After one-month of stopping the drug, the lesions cleared. This case highlights the importance of maintaining good oral hygiene and periodic dental review in patients on antiseizure medications.
format Online
Article
Text
id pubmed-9733520
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-97335202022-12-10 Levetiracetam-induced gingival hyperplasia James, J Jose, J Gafoor, VA J Postgrad Med ADR Report Levetiracetam is a new generation antiseizure medication which binds to synaptic vesicle protein SV2A and inhibits the release of neurotransmitters. Gingival hyperplasia is a common side effect of conventional antiseizure medications like phenytoin, but very rare with the newer ones. A 14-year-old boy was started on levetiracetam 250 mg twice daily after a generalized seizure. Five days later he presented with gingival swelling and painful oral aphthae, without lymphadenopathy or systemic symptoms. Blood investigations were normal. After one-month of stopping the drug, the lesions cleared. This case highlights the importance of maintaining good oral hygiene and periodic dental review in patients on antiseizure medications. Wolters Kluwer - Medknow 2022 2022-06-23 /pmc/articles/PMC9733520/ /pubmed/35848684 http://dx.doi.org/10.4103/jpgm.jpgm_1059_21 Text en Copyright: © 2022 Journal of Postgraduate Medicine https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle ADR Report
James, J
Jose, J
Gafoor, VA
Levetiracetam-induced gingival hyperplasia
title Levetiracetam-induced gingival hyperplasia
title_full Levetiracetam-induced gingival hyperplasia
title_fullStr Levetiracetam-induced gingival hyperplasia
title_full_unstemmed Levetiracetam-induced gingival hyperplasia
title_short Levetiracetam-induced gingival hyperplasia
title_sort levetiracetam-induced gingival hyperplasia
topic ADR Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733520/
https://www.ncbi.nlm.nih.gov/pubmed/35848684
http://dx.doi.org/10.4103/jpgm.jpgm_1059_21
work_keys_str_mv AT jamesj levetiracetaminducedgingivalhyperplasia
AT josej levetiracetaminducedgingivalhyperplasia
AT gafoorva levetiracetaminducedgingivalhyperplasia